Overview

A Study of Guselkumab in Adult Participants With Celiac Disease

Status:
Recruiting
Trial end date:
2023-02-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of guselkumab compared to placebo in participants with celiac disease.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Antibodies, Monoclonal